|
Pandemrix is an influenza vaccine for influenza pandemics, such as the H1N1 2009 flu pandemic colloquially called the swine flu. The vaccine was developed by GlaxoSmithKline〔 〕 and patented in September 2006. The vaccine is one of the H1N1 vaccines approved for use by the European Commission in September 2009 upon the recommendations of the European Medicines Agency (EMEA).〔(EMEA Pandemrix page )〕 The vaccine is only approved for use when an H1N1 influenza pandemic has been officially declared by the World Health Organization (WHO) or European Union (EU).〔 This vaccine was initially developed as a pandemic mock-up vaccine using an H5N1 strain.〔 (【引用サイトリンク】 title=Assessment report for the mock-up H5N1 vaccine )〕 In August 2010, The Swedish Medical Products Agency (MPA) and The Finnish National Institute for Health and Welfare (THL) launched investigations regarding the acquirement of narcolepsy as a possible side effect to Pandemrix flu vaccination in children, and found a minimum 6.6 fold increased risk among children and youths, resulting in a minimum of 3.6 additional cases of narcolepsy per 100,000 vaccinated subjects.〔( Report from an epidemiological study in Sweden on vaccination with Pandemrix and narcolepsy ), Swedish medical product agency, June 30, 2011.〕 ==Constituents== As well as the active antigen derived from A/California/7/2009 (H1N1), the vaccine contains an immunologic adjuvant AS03 which consists of DL-α-tocopherol (vitamin E), squalene and polysorbate 80. Thiomersal (thimerosal) is added as a preservative. Being manufactured in chicken eggs, it contains trace amounts of egg proteins. Additional important non-medicinal ingredients are formaldehyde, sodium deoxycholate, and sucrose.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Pandemrix」の詳細全文を読む スポンサード リンク
|